InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.021 0.012 (127.78%)+
Announcement
Release
2 Mar 2026 9:23AM
Price at Release
$0.009
Full Release
download
Summary
Avecho Biotechnology Limited has successfully completed the recruitment for the interim analysis cohort of its pivotal Phase III clinical trial for a TPM®-enhanced cannabidiol (CBD) capsule aimed at treating insomnia. With approximately 210 participants enrolled, the interim analysis results, anticipated in June 2026, are expected to be a significant milestone for the company's insomnia program. This trial is designed to support the capsule's registration with Australia’s Therapeutic Goods Administration (TGA). Avecho has secured a commercial partnership with Sandoz AG for the Australian market and is pursuing additional licensing opportunities globally. The company aims to leverage Australia’s unique over-the-counter CBD registration pathway, with the CBD market in Australia projected to exceed USD 125 million annually.
Key Points
  • Avecho Biotechnology Limited completed recruitment for the interim analysis cohort of its Phase III trial.
  • The trial involves approximately 210 patients and will analyze the efficacy of the TPM®-enhanced cannabidiol (CBD) capsule for insomnia.
  • Interim analysis results are expected in June 2026.
  • Avecho has a commercial partnership with Sandoz AG for the Australian market.
  • The Phase III trial is crucial for registration with the Therapeutic Goods Administration (TGA) in Australia.
  • Avecho aims to capitalize on Australia's over-the-counter CBD registration pathway.
  • The global insomnia market is projected to be valued at USD 5.22 billion in 2024.
  • Avecho is in discussions for licensing the product outside Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.